Quantcast

Latest leukemia Stories

2014-07-23 16:28:25

WHITE PLAINS, N.Y., July 23, 2014 /PRNewswire-USNewswire/ -- Today's U.S. Food and Drug Administration (FDA) approval of idelalisib to treat patients with relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma (FL) and small lymphocytic lymphoma (SLL) is a significant advance for patients with these blood cancers. Idelalisib, which goes by the trade name Zydelig®, is a first-in-class inhibitor of PI3K delta, a protein that is highly expressed in many B-cell malignancies...

2014-07-18 23:04:42

NFCR supported scientist Laurence Cooper, M.D., Ph.D., and his team at the MD Anderson Cancer Center have engineered a novel treatment for killing fungal infections that are often lethal to cancer patients with weakened immune systems. Bethesda, MD (PRWEB) July 18, 2014 NFCR supported scientist Laurence Cooper, M.D., Ph.D., and his team at the MD Anderson Cancer Center have engineered a novel treatment for killing fungal infections that are often lethal to cancer patients with weakened...

2014-07-17 12:29:31

-COMMUNITY LEADERS RAISED $30.5 MILLION TO HELP FIND CANCER CURES- WHITE PLAINS, N.Y., July 17, 2014 /PRNewswire/ -- A Chicago man and Los Angeles woman raised $386,284 and $343,962, respectively, to support The Leukemia & Lymphoma Society's (LLS) mission to find cures for blood cancers and ensure that patients have access to lifesaving treatments. As the leading fundraisers in the 2014 Man & Woman of the Year campaign, the 24(th) year for this prestigious program, these...

2014-07-16 12:28:26

WHITE PLAINS, N.Y., July 16, 2014 /PRNewswire-USNewswire/ -- James Davis, Ph.D., JD, a consultant in crisis management and the launch of new technologies for biotechnology and other companies, has been elected chairman of the national board of directors of The Leukemia & Lymphoma Society (LLS), effective July 1. LLS is the world's largest voluntary health agency dedicated to finding cures and ensuring access to treatments for patients with blood cancers. Davis is the former...

2014-07-15 12:29:21

The Upcoming Entry of New Generation TKIs will Challenge the Established Position of CML Treatments in Brazil and Mexico, According to Findings from Decision Resources Group BURLINGTON, Mass., July 15, 2014 /PRNewswire/ -- Decision Resources Group finds that, despite the fact that the treatment armamentarium for chronic myeloid leukemia (CML) in Brazil and Mexico includes all three tyrosine kinase inhibitors (TKIs)--Novartis' Glivec (imatinib), Bristol-Myers Squibb's Sprycel (dasatinib) and...

2014-07-14 12:55:18

The Lancet Failure to get the best treatment and variations in the quality of care are the most likely reasons why survival for blood cancer patients still varies widely between regions within Europe, according to the largest population-based study of survival in European adults to date, published in The Lancet Oncology. "The good news is that 5-year survival for most cancers of the blood has increased over the past 11 years, most likely reflecting the approval of new targeted drugs in...

2014-07-14 12:24:41

Surveyed Payers Formulary Placement of Novel Agents is Likely to be Influenced by Breakthrough Therapy Designation, According to Findings from Decision Resources Group BURLINGTON, Mass., July 14, 2014 /PRNewswire/ -- Decision Resources Group finds that breakthrough therapy designation is likely to positively influence perceptions of emerging drugs for both oncologists and payers. Results of a survey of 100 oncologists (50 medical oncologists and 50 hematological oncologists) and 30 medical...

2014-07-14 08:26:44

WHITE PLAINS, N.Y., July 14, 2014 /PRNewswire/ -- Burlington and The Leukemia & Lymphoma Society's (LLS) Light The Night® Walk fundraising campaign have partnered once again to raise money for blood cancer research. Burlington, the #1 National Corporate Light The Night partner, launches its 13(th) consecutive company-wide initiative today by encouraging its customers to make a donation at checkout to benefit LLS. As part of this year's promotion, five young blood cancers...

2014-07-10 12:30:41

WINDSOR, England, July 10, 2014 /PRNewswire/ -- Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency (EMA) for use of its pegylatedL-asparaginase, Oncaspar(R) (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen. (Logo: http://photos.prnewswire.com/prnh/20140710/696813 ) The submission is...

2014-07-09 16:25:02

LONDON, July 9, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 https://www.reportbuyer.com/product/2225869/OpportunityAnalyzer-Chronic-Lymphocytic-Leukemia---Opportunity-Analysis-and-Forecasts-to-2018.html OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 SummaryChronic lymphocytic leukemia (CLL), the most common...


Latest leukemia Reference Libraries

Clinical Leukemia
2012-05-18 15:34:28

Clinical Leukemia is a peer-reviewed medical journal published by CIG Media Group. The journal publishes articles on detection, diagnosis, prevention, and treatment of leukemia. The main emphasis is on recent scientific developments in all areas related to leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance, gene and antisense therapy; pathology, markers, and prognostic indicators, chemoprevention strategies,...

More Articles (1 articles) »
Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related